IMPACT-AFib: An 80,000 Person Randomized Trial Using the FDA Sentinel System Platform

January 5, 2018 – NIH Collaboratory Grand Rounds

Christopher Granger, MD
Sean Pokorney, MD
Duke Clinical Research Institute

Richard Platt, MD
Noelle Cocoros, DSc
Department of Population Medicine, Harvard Medical School & Harvard Pilgrim Health Care Institute
Outline

- FDA’s Sentinel System, FDA-Catalyst in brief
- The public health importance of atrial fibrillation
- IMPACT-AFib – trial design
- Current status and baseline data
- Lessons learned
Outline

• FDA’s Sentinel System, FDA-Catalyst in brief
• The public health importance of atrial fibrillation
• IMPACT-AFib – trial design
• Current status and baseline data
• Lessons learned
Sentinel is a National Medical Product Monitoring System

LEARN MORE

SAFEY

ABOUT
- Background
- Coordinating Center
- Privacy and Security
- The Sentinel System Story
- Reagan-Udall Foundation and IMEDS

MEDICAL PRODUCT ASSESSMENTS
- Active Risk Identification and Analysis System
- Ongoing ARIA Assessments
- Assessments of Drugs
- Assessments of Vaccines, Blood, & Biologics
- FDA-Catalyst

Latest Postings

SPOTLIGHT
- CDER Conversation: The FDA's Sentinel Initiative
  Mon, 11/27/2017

PUBLICATIONS AND PRESENTATIONS
- Development of Metrics to Assess Appropriate Prescribing of Opioids in the Mini-Sentinel Distributed Database (MSDD)
  Mon, 11/20/2017
Curated Distributed Data Using a Common Data Model

Quality of Care

Medical Product Safety Surveillance

Clinical Research

Comparative Effectiveness

Public Health Surveillance

Sentinel

Randomized Clinical Trials

IMPACT-AFib
MINI-SENTINEL and CLINICAL TRIALS TRANSFORMATION INITIATIVE
DEVELOPING APPROACHES TO CONDUCTING RANDOMIZED TRIALS USING THE MINI-SENTINEL DISTRIBUTED DATABASE

February 28, 2014
FDA-Catalyst: IMPACT-AFib randomized trial

IMplementation of a randomized controlled trial to improve treatment with oral AntiCoagulants in patients with Atrial Fibrillation

• Direct mailer to health plan members with AFib, high risk for stroke and no oral anticoagulant (OAC) treatment, and to their providers, to encourage consideration of OACs
Outline

• FDA’s Sentinel System, FDA-Catalyst in brief
• The public health importance of atrial fibrillation
• IMPACT-AFib – trial design
• Current status and baseline data
• Lessons learned
What is Atrial Fibrillation?

Normal heart:
- Sinus node impulse
- Impulse passes through atrioventricular node
- Ventricular impulses

Heart with atrial fibrillation:
- Chaotic signals passing through AV node
- Atrial fibrillating impulses
- Rapid ventricular impulses

IMPACT-AFib
Atrial fibrillation, a common and important problem

- Over 5 million people in the United States have AFib
  - 2% of people younger than age 65
  - 9% of people aged ≥65 years
- 5 fold increase in risk of stroke
  - 15-20% of ischemic strokes are due to AFib
- Contributes to 130,000 deaths
- $6 billion added annual cost ($8,700 per person with AFib)

www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_atrial_fibrillation.htm
Anticoagulation Prevents a Majority of Strokes

### Warfarin compared to control or placebo

<table>
<thead>
<tr>
<th>Trial</th>
<th>Relative Risk Reduction (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AFASAK I (1990)</td>
<td>100%</td>
</tr>
<tr>
<td>SPAF I (1991)</td>
<td>50%</td>
</tr>
<tr>
<td>BAATAF (1990)</td>
<td>0%</td>
</tr>
<tr>
<td>CAFA (1991)</td>
<td>−50%</td>
</tr>
<tr>
<td>SPINAF (1992)</td>
<td>−100%</td>
</tr>
<tr>
<td>EAFT (1993)</td>
<td>Favors placebo or control</td>
</tr>
<tr>
<td>Combined</td>
<td>Favors warfarin</td>
</tr>
</tbody>
</table>

**RRR 64%**

**Warfarin vs. Placebo or Control**

(6 trials, total n=2,900)


### NOAC compared to warfarin

<table>
<thead>
<tr>
<th>Trial</th>
<th>Relative Risk Reduction (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RE-LY (2009)</td>
<td>50%</td>
</tr>
<tr>
<td>ROCKET AF (2011)</td>
<td>0%</td>
</tr>
<tr>
<td>ARISTOTLE (2011)</td>
<td>−50%</td>
</tr>
<tr>
<td>ENGAGE AF-TIMI 48 (2013)</td>
<td>−100%</td>
</tr>
<tr>
<td>Combined</td>
<td>Favors NOAC</td>
</tr>
</tbody>
</table>

**RRR 19%**

**Non-vitamin K antagonist Oral Anticoagulant (NOAC)**

vs. Warfarin

(4 trials, total n=71,683)

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>If patient has risk factor, add points</th>
</tr>
</thead>
<tbody>
<tr>
<td>C Congestive Heart Failure</td>
<td>+1</td>
</tr>
<tr>
<td>H High Blood Pressure (hypertension, including normal blood pressure on blood pressure medications)</td>
<td>+1</td>
</tr>
<tr>
<td>$A_2$ Age 75 years old or older</td>
<td>+2</td>
</tr>
<tr>
<td>D Diabetes</td>
<td>+1</td>
</tr>
<tr>
<td>$S_2$ Stroke or TIA (mini-stroke)</td>
<td>+2</td>
</tr>
<tr>
<td>V Vascular Disease (prior bypass surgery, heart attack peripheral artery disease, or aortic plaque)</td>
<td>+1</td>
</tr>
<tr>
<td>$A$ Age 65-74 years</td>
<td>+1</td>
</tr>
<tr>
<td>$Sc$ Sex Category: Female sex</td>
<td>+1</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>TOTAL</strong></td>
</tr>
</tbody>
</table>
Anticoagulation Use in RE-LY Registry

In North America, non-rheumatic AF, CHADS ≥ 2, 52% on OAC

Circulation. 2014;129:1568-1576
# Rates of Anticoagulation for Atrial Fibrillation – Preliminary Sentinel Data

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Potentially eligible members (Aetna, Humana, Harvard Pilgrim)</td>
<td>16.2 million</td>
</tr>
<tr>
<td>Patients with &gt;1 AF diagnosis</td>
<td>231,696 (1.4% of all members)</td>
</tr>
<tr>
<td>AF pts with CHA₂DS₂-VASc ≥ 2</td>
<td>201,882 (87% of AF patients)</td>
</tr>
<tr>
<td>Patients with at least one oral anticoagulation fill</td>
<td>105,256 (52% of AF patients with CHA₂DS₂-VASc ≥ 2)</td>
</tr>
<tr>
<td>Proportion of days covered by anticoagulation in AF patients</td>
<td>32%</td>
</tr>
</tbody>
</table>

Pokorney S et al. Am College of Cardiol 2016
Interventions (including patient education) can be effective at increasing the proportion of patients with Afib and risk for stroke who are treated with oral anticoagulation.

A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial

Dragos Vinereanu, Renato D Lopes, M Cecilia Bahit, Denis Xavier, Jie Jiang, Hussein R Al-Khalidi, Wensheng He, Ying Xian, Andrea O Ciobanu, Deepak Y Kamath, Kathleen A Fox, Meena P Rao, Sean D Pokorney, Otavio Berwanger, Carlos Tajer, Pedro G M de Barros e Silva, Mayme L Roettig, Yong Huo, Christopher B Granger, on behalf of the IMPACT-AF investigators*

The Lancet (published online August 28 2017)
Rationale for IMPACT-AFib trial

• OAC underuse is a public health priority
• Also a priority of health plans
• Interventions (mailings) are consistent with routine health plan interventions
• Eligible population are identifiable and major outcomes measurable using Sentinel Distributed Database
Outline

• FDA’s Sentinel System, FDA-Catalyst in brief
• The public health importance of atrial fibrillation
• IMPACT-AFib – trial design
• Current status and baseline data
• Lessons learned
IMPACT-Afib Workgroup

Patient representative

[Logos of companies and organizations]
Inclusion Criteria

• ≥30 years old
• Medical & pharmacy coverage for ≥365 days
• ≥2 atrial fibrillation diagnosis codes with 1 in the last year
• No OAC fill within the previous 12 months
• CHA₂DS₂-VASc score ≥2
Exclusion Criteria

- Any OAC dispensing within the last year (or ≥4 INRs)
- Conditions other than AF that require anticoagulation
- Any history of intracranial hemorrhage
- Bleeding related hospitalization in the last 6 months
- Current pregnancy
- P2Y12 inhibitor treatment, e.g., clopidogrel within 90 days
Patients with AFib, CHADS-VASc $\geq 2$

**RANDOMIZE**

- Usual Care and Delayed Provider intervention
- Early Patient-level and Provider-level intervention

**Early Intervention**

- Access Pharmacy Records
  - OAC in prior 12 months
    - Excluded
  - No OAC in prior 12 months
    - Intervention Mailed

**12-months**
**Primary outcome:** Proportion of AFib patients started on OAC over the course of the 12-month trial

**Secondary outcomes:**
- Proportion of days covered with OAC prescription
- Number of patients on OAC at end of one year
- Admissions for stroke or TIA
- Admissions for stroke
- Admissions for bleeding
- Deaths (subset)
Intervention Materials

PATIENTS
- Letter from health plan
- Patient brochure – information on AF and OACs
- Patient pocket card – designed to facilitate conversation between patient and provider

PROVIDERS
- Letter from health plan
- Provider enclosure – myths and facts on OACs
- Response mailer – providers to share feedback
MEMBER LETTER

According to our records, you may have been diagnosed with atrial fibrillation. We know that managing your health can be a challenge, and hope this information about how to lower your risk for stroke will help.

**People who have the heartbeat irregularity known as “atrial fibrillation” are at an increased risk of having a stroke.**

Please visit [www.IMPACT-AFib.org](http://www.IMPACT-AFib.org) to learn more about atrial fibrillation, stroke risk, and anticoagulant medications. More information about the IMPACT-AFib initiative is available by calling [XXX-XXX-XXXX] or emailing [name@duke/healthplan.ext]

If you have questions about your benefits, call the number on the back of your health plan ID card.

**Talk to your doctor about anticoagulant medications.**

This packet contains information about the benefits of taking anticoagulant medications, also called blood thinners, to lower your risk of having a stroke. We recommend that you bring this information packet to your next doctor’s appointment. We sent similar information to your doctor.

Anticoagulant medications may not be right for all patients, but they might be right for you. Even if you have talked about this with your doctor in the past, we encourage you to have another conversation about these medications. New anticoagulant medications are safe and effective options for many patients.

**Protecting your health information**

We take protecting your health information seriously. None of your health information has been shared with other health organizations. Only you and your doctor were sent this information.

Sincerely,

Chief Medical Officer

Enclosures

If you have any questions, please contact [name] at [phone #] or [email]
Dear Provider:

As part of our effort to improve the use of oral anticoagulant medications for stroke prevention in patients with atrial fibrillation (AFib), we would like to introduce you to the IMPACT-AFib initiative. The objective of the IMPACT-AFib initiative is to increase awareness and education among patients and you. This FDA-sponsored initiative is being conducted by [HEALTH PLAN] in collaboration with researchers at Harvard and Duke.

Educational materials were sent to patient(s) who appear to have atrial fibrillation, have high stroke risk (CHA2DS2-VASc score ≥ 2), and have no record available to us of having filled a prescription for an anticoagulant in the past year. Please see the next page for a list of patients who received these materials.

Facts about atrial fibrillation

- Patients with AFib have a five times higher stroke risk relative to patients without AFib (Circulation 2011;123(10):e269-369).
- 50% of patients with AFib and high stroke risk have not filled an anticoagulant prescription (Circulation 2014; 129 (15), 1569-1576).

Common misconceptions about stroke prevention

Aspirin is good enough

- Aspirin reduces stroke by < 20%, if at all, compared with 70% reduction with anticoagulation; therefore, aspirin is not sufficiently effective for stroke prevention.¹

Patients with AFib are at greater risk of bleeding than stroke

- 30% of elderly patients fall in a year, but a patient would need to fall nearly every day before the risk of intracranial bleeding outweighs the benefits of anticoagulants.²
- The risk of recurrent GI bleeding averages 1.2% per year, but would have to exceed 10% before the risk of GI bleeding outweighs the benefit of anticoagulants.³

There are appropriate reasons for patients to not take an anticoagulant, including pregnancy and history of intracranial hemorrhage. A response mailer is enclosed for you to share these reasons, should they exist for your patient(s).


What should you do?

Please review and discuss anticoagulation and stroke risk with your patient(s) at their next visit.

For Health Plan pharmacy coverage policy, go to www.HealthPlan.com. You can visit www.Impact-AFib.org or call xxx-xxx-xxxx or email [name@duke/healthplan.ext] for more information about this initiative.

If you have questions or concerns, please contact us at [MD@HealthPlan.com or xxx-xxx-xxxx].

Enclosed is an information card and the patient information.

Sincerely,

Chief Medical Officer
Health Plan

<table>
<thead>
<tr>
<th>Name</th>
<th>Date of Birth</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This packet and the packet sent to your patient(s) are funded by the IMPACT-AFib Initiative. This U.S. Food and Drug Administration-sponsored research study is being conducted by [Health Plan]. In collaboration with researchers at Harvard Pilgrim Health Care Institute and the Duke Clinical Research Institute. The goal of this initiative is to improve the use of oral anticoagulant medications for stroke prevention in patients with atrial fibrillation.

Disclaimer: Lorem ipsum dolor sit amet, est donum semper pharetra end, mus ac nec utiles id, dictum condimentum massa non dapibus. In iusto vestibulum purus. Sociis, aener amure nec quis inc.
If we have incorrectly identified a patient as being able to benefit from taking an oral anticoagulant, we would like to hear from you.

Please complete the information below, then seal and return this mailer.

---

**IMPACT-AFib**

---

Patient name: __________________________

Date of Birth: _____ / _____ / 19____

Should not be prescribed an oral anticoagulant because— (please check all that apply)

- [ ] He/she is not my patient and/or I am not the prescribing physician
- [ ] Patient does not have atrial fibrillation
- [ ] Patient already takes an anticoagulant
- [ ] An anticoagulant has already been prescribed
- [ ] Very high risk of major/life-threatening bleeding
- [ ] Unable to tolerate warfarin
- [ ] Unable to afford a non-vitamin K oral anticoagulant
- [ ] Patient decision after thorough review of risks, benefits, concerns
- [ ] Other (please explain): ____________________________________________
Outline

• FDA’s Sentinel System, FDA-Catalyst in brief
• The public health importance of atrial fibrillation
• IMPACT-AFib – trial design
• Current status and baseline data
• Lessons learned
Patients Contacted via Mailing

Early Intervention Launch

25-Sep-17  25-Oct-17  25-Nov-17  25-Dec-17
Age and Sex Distribution by Group

Mean CHADS-VASc score of 5
Members in Early Intervention Arm

- On treatment: $n = 76,696$
- Not on treatment: $n = 43,826$

36% were not on treatment at time of randomization.
Outline

• FDA’s Sentinel System, FDA-Catalyst in brief
• The public health importance of atrial fibrillation
• IMPACT-AFib – trial design
• Current status and baseline data
• Lessons learned
Good practices (lessons not to forget)

| Early project preparation | • Involvement of health plans from the very beginning  
|                           | • Need for buy in from clinical leadership  
|                           | • Adequate funding / resources for all sites from the start  
| Patient engagement        | • Patient advocate on project team - guidance on intervention design as well as cohort inclusion (e.g. patients ≥30)  
|                           | • Patient advocate on project as well as patient and provider focus groups not planned from the start but provided key information for intervention materials (e.g. response mailer)  
| IRB approach              | • Single IRB facilitates process across multiple institutions  
|                           | • Commercial IRB most efficient (meet more regularly, have more streamlined processes in place, have cross-jurisdictional expertise)  
|                           | • Waiver of consent obtained  
| Timing of trial start and mailings | • Annual open enrollment and other key points in time had to be accommodated when planning for trial execution  

### Lessons learned (1)

<table>
<thead>
<tr>
<th>Similar initiatives at health plans</th>
<th>At 2 health plans: non-research initiatives underway include written outreach to members with AF at high risk of stroke</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trial design and protocol</td>
<td>Many iterations necessary to finalize protocol due to need for agreement by clinical management teams from all sites</td>
</tr>
<tr>
<td>Intervention materials</td>
<td>Branding, logos, details of materials required substantial discussion, lengthy review processes at each health plan</td>
</tr>
<tr>
<td>Medicare/Medicaid beneficiaries participants</td>
<td>Health plan concerns re inclusion of members with Medicare Advantage (complaint from such members could impact Star ratings); letter of support was obtained from the CMS</td>
</tr>
</tbody>
</table>
### Lessons learned (2)

<table>
<thead>
<tr>
<th>Code list review</th>
<th>Clinician reviewed thousands of codes (ICD-9, 10) for elements of CHADS-VASC score and other conditions</th>
</tr>
</thead>
</table>
| Underestim. of sample size | Combination of changes in definitions and limitations of approach yielded underestimate  
|                   | Sample size and budget were based on underestimate                                                      |
| “Facility” as provider | 20-40% of all providers identified by workplan were actually facilities                                    |
| Members whose AF dx codes likely rule outs | Evident after follow-up on initial calls received to project phone line  
|                   | Can Common Data Model help with this?                                                                     |
| Ethics issues | Questions raised about delaying contact of the usual care group                                          |
Acknowledgements

• **Aetna**: Cheryl Walraven, Annemarie Kline, Daniel Knecht
• **Clinical Trials Transformation Initiative**: Jennifer Goldsack
• **Duke Clinical Research Institute**: Hussein Al-Khalidi, Wensheng He, Emily O’Brien, Jennifer Rymer, Sana Al-Khatib
• **DPM/HPHCI**: Crystal Garcia, Robert Jin, Hana Lipowicz
• **HealthCore**: Kevin Haynes, Lauren Parlett
• **Humana**: Vinit Nair, Thomas Harkins, Yunping Zhou
• **Optum**: Nancy Lin
• **Patient Representative**: Debbé McCall
• **U.S Food & Drug Administration**: Jacqueline Corrigan-Curay, Dianne Paraoan, David Martin, Melissa Robb, Patrick Archdeacon
Thank you!
<table>
<thead>
<tr>
<th></th>
<th>All Randomized with AFib</th>
<th>Delayed intervention, prior to assessing treatment</th>
<th>Early intervention, prior to assessing treatment</th>
<th>Early intervention, not on treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Totals</strong></td>
<td>241,044</td>
<td>120,522</td>
<td>120,522</td>
<td>43,826</td>
</tr>
<tr>
<td><strong>Age</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30-64</td>
<td>No. 20,175</td>
<td>% 8.4</td>
<td>No. 10,085</td>
<td>% 8.4</td>
</tr>
<tr>
<td></td>
<td>No. 10,090</td>
<td>% 8.4</td>
<td>No. 10,090</td>
<td>% 8.4</td>
</tr>
<tr>
<td></td>
<td>No. 3,525</td>
<td>% 8.0</td>
<td>No. 5,286</td>
<td>% 12.1</td>
</tr>
<tr>
<td>65-69</td>
<td>No. 28,936</td>
<td>% 12</td>
<td>No. 14,424</td>
<td>% 12</td>
</tr>
<tr>
<td></td>
<td>No. 14,512</td>
<td>% 12</td>
<td>No. 14,512</td>
<td>% 12</td>
</tr>
<tr>
<td></td>
<td>No. 5,286</td>
<td>% 12.1</td>
<td>No. 8,057</td>
<td>% 18.4</td>
</tr>
<tr>
<td>70-74</td>
<td>No. 45,838</td>
<td>% 19</td>
<td>No. 22,948</td>
<td>% 19</td>
</tr>
<tr>
<td></td>
<td>No. 22,890</td>
<td>% 19</td>
<td>No. 22,890</td>
<td>% 19</td>
</tr>
<tr>
<td></td>
<td>No. 8,057</td>
<td>% 18.4</td>
<td>No. 8,057</td>
<td>% 18.4</td>
</tr>
<tr>
<td>75-79</td>
<td>No. 51,636</td>
<td>% 21.4</td>
<td>No. 25,817</td>
<td>% 21.4</td>
</tr>
<tr>
<td></td>
<td>No. 25,819</td>
<td>% 21.4</td>
<td>No. 25,819</td>
<td>% 21.4</td>
</tr>
<tr>
<td></td>
<td>No. 8,691</td>
<td>% 19.8</td>
<td>No. 8,691</td>
<td>% 19.8</td>
</tr>
<tr>
<td>80+</td>
<td>No. 94,459</td>
<td>% 39.2</td>
<td>No. 47,248</td>
<td>% 39.2</td>
</tr>
<tr>
<td></td>
<td>No. 47,211</td>
<td>% 39.2</td>
<td>No. 47,211</td>
<td>% 39.2</td>
</tr>
<tr>
<td></td>
<td>No. 18,267</td>
<td>% 41.7</td>
<td>No. 18,267</td>
<td>% 41.7</td>
</tr>
<tr>
<td><strong>Female</strong></td>
<td>No. 112,500</td>
<td>% 46.7</td>
<td>No. 56,085</td>
<td>% 46.5</td>
</tr>
<tr>
<td></td>
<td>No. 56,415</td>
<td>% 46.8</td>
<td>No. 56,415</td>
<td>% 46.8</td>
</tr>
<tr>
<td></td>
<td>No. 21,171</td>
<td>% 48.3</td>
<td>No. 21,171</td>
<td>% 48.3</td>
</tr>
<tr>
<td><strong>CHADS-VASC</strong></td>
<td>Mean 5 (1.7)</td>
<td>Mean 5 (1.6)</td>
<td>Mean 5 (1.7)</td>
<td>Mean 5 (1.7)</td>
</tr>
<tr>
<td></td>
<td>(SD)</td>
<td>(SD)</td>
<td>(SD)</td>
<td>(SD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NA</td>
</tr>
</tbody>
</table>
How can I keep myself safe from bleeding and falls?
(As with other medications, there is a risk of experiencing side effects while taking anticoagulants. The main side effect is that you can bleed too easily.)
- Use a soft bristle toothbrush and waxed dental floss
- Use an electric razor to shave
- Be careful with sharp objects: toothpicks, knives, tools, scissors, etc.
- Wear shoes or non-skid slippers at all times
- Avoid nonsteroidal anti-inflammatory drugs like ibuprofen, naproxen, etc.
- Be careful when trimming toenails or callouses
- Avoid activities that increase risk of falls or involve hard contact, such as contact sports

Is it OK to take an anticoagulant medication if I have had bleeding? What if I fall?
- If you are at high risk for bleeding, the use of an anticoagulant medication depends on whether the benefit of preventing a stroke is more important than the risk of bleeding. Talk with your doctor about your risk.
- The benefits of preventing stroke outweigh the risk of bleeding for many people who might fall.

If I have bleeding, is there something to reverse the effect of anticoagulant medications? An antidote?
- Yes, there are antidotes for warfarin and Pradaxa
- Reversal drugs are in development for other anticoagulant medications
- There is no antidote for aspirin

Will an anticoagulant medicine interact with other medicines or foods?
- Warfarin interacts with foods that are high in vitamin K
  - You should ask your doctor or pharmacist for a list of food interactions
  - Xarelto should be taken with food to help your body absorb the medicine

Talk with your doctor or pharmacist if you have questions about any medications or foods that might affect your anticoagulant medication, including nonprescription medicines, vitamins, and herbal supplements.

Am I at risk for stroke?
- The CHA₂DS₂-VASc calculates stroke risk for patients with atrial fibrillation.
- Complete the following CHA₂DS₂-VASc calculator to determine your personal risk.
- If you have AFib and a CHA₂DS₂-VASc score of 2 or greater, you have an increased risk of stroke.

<table>
<thead>
<tr>
<th>CHA₂DS₂-VASc RISK SCORE</th>
<th>If yes, add points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Do you have congestive heart failure?</td>
<td>+1</td>
</tr>
<tr>
<td>Do you have high blood pressure or are you taking blood pressure medication(s)?</td>
<td>+1</td>
</tr>
<tr>
<td>Are you between 65–74 years of age?</td>
<td>+1</td>
</tr>
<tr>
<td>Are you 75 years old or older?</td>
<td>+2</td>
</tr>
<tr>
<td>Do you have diabetes?</td>
<td>+1</td>
</tr>
<tr>
<td>Have you ever had a stroke or TIA (mini-stroke)</td>
<td>+2</td>
</tr>
<tr>
<td>Have you ever had vascular disease (bypass surgery, heart attack, peripheral artery disease, or aortic plaque)?</td>
<td>+1</td>
</tr>
<tr>
<td>Are you female?</td>
<td>+1</td>
</tr>
</tbody>
</table>

MY TOTAL
Patients with atrial fibrillation (AFib) are at five times higher risk of stroke (Circulation 2011;123(10):e269–367)

- Two-thirds of strokes in patients with atrial fibrillation are preventable with anticoagulation, as recommended in clinical practice guidelines (Annals of internal medicine 146.12 (2007): 857–867)
- Despite this guideline, at least 50% of patients with a CHA₂DS₂-VASc score of 2 or higher are not being prescribed an oral anticoagulant (Circulation 2014; 129 (15), 1568–1576)

You can change these statistics by—

- Educating all of your patients with AFib about anticoagulant use
- Stopping the use of aspirin as an anticoagulant

For more information visit www.IMPACT-AFib.org

<table>
<thead>
<tr>
<th>Myth vs. Reality</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Myth:</strong> Aspirin prevents stroke and is safe</td>
</tr>
<tr>
<td><strong>Reality:</strong> Aspirin is neither safe nor effective (Eur Heart J 2015;36:653-6)</td>
</tr>
<tr>
<td><strong>Myth:</strong> It is risky to resume oral anticoagulation therapy in the months after bleeding</td>
</tr>
<tr>
<td><strong>Reality:</strong> Benefits generally outweigh risks (Arch Intern Med 2002;162:541-550)</td>
</tr>
<tr>
<td><strong>Myth:</strong> It is risky to prescribe oral anticoagulants to patients who are at risk of falling</td>
</tr>
<tr>
<td><strong>Reality:</strong> “... persons taking warfarin must fall about 295 times in 1 year for warfarin to not be the optimal therapy.” (Arch Intern Med 1999;159:677-685)</td>
</tr>
<tr>
<td><strong>Myth:</strong> Patients who don’t tolerate warfarin won’t tolerate any oral anticoagulant</td>
</tr>
<tr>
<td><strong>Reality:</strong> Most patients tolerate novel oral anticoagulants (N Engl J Med 2011;364:806-17)</td>
</tr>
<tr>
<td><strong>Myth:</strong> Patients with paroxysmal AFib are low risk of stroke</td>
</tr>
<tr>
<td><strong>Reality:</strong> Risk is about the same for paroxysmal or permanent AFib, indicating need for anticoagulation (Circulation 2014;130: e199-e267)</td>
</tr>
<tr>
<td><strong>Myth:</strong> There is no antidote for novel oral anticoagulants</td>
</tr>
<tr>
<td><strong>Reality:</strong> An injectable reversal agent (Praxbind) is available for the novel oral anticoagulant Pradaxa (dabigatran). (N Engl J Med. 2015;373:511-20)</td>
</tr>
</tbody>
</table>
Reasons for not using OAC for AF with risk factors

Legitimate
- Very high risk of major/life-threatening bleeding
- Unable to tolerate warfarin and unable to afford NOAC
- Patient decision after thorough review of risks, benefits, concerns

Illegitimate
- Aspirin is effective
- Belief that asymptomatic or minimal AF has a low stroke risk
- Some risk of bleeding that does not outweigh stroke reduction benefit (prior bleeding, typical falls, etc)
- Lack of a reversal agent